Profile | OTHERS

Logo	Name	Type	Year of Establishment	Industry Tag
	Accel	Investor	1983	Medical
Hi we’re Accel! Accel is a global venture capital firm based in Palo Alto, California, supporting exceptional founders from seed through growth stage with a focus on transformative technologies. In synthetic biology, Accel led Biostate AI’s $12?M Series?A—backing its AI?enabled RNA sequencing platform and foundation model approach to molecular diagnostics and therapeutics .
	Catapult Ventures	Investor	2017	Investor
Hi we’re Catapult Ventures! Catapult Ventures is a UK-based VC firm with a life sciences fund dedicated to early-stage startups, including those in agricultural synthetic biology. They notably invested in CroBio—an engineered microbe developer creating water-retaining soil matrices—demonstrating their commitment to bio-based innovation in agriculture
	Vision Plus Capital	Investor	2015	Investor
Hi we’re Vision Plus Capital! Vision Plus Capital (China) is a Hangzhou-headquartered early-stage VC firm founded by Alibaba co?founder Eddie?Wu in 2015, with ~US?$1.4–2?billion AUM and active investment across China, the U.S., and EMEA . Though focused broadly on deep tech, health tech, and digital healthcare, Vision Plus has demonstrated strategic interest in biotech and synthetic biology, exemplified by co-investment in platforms at the intersection of AI and molecular diagnostics like Biostate AI’s Series?A round
	Matter Venture Partners	Investor	2023	Investor
Hi we’re Matter Venture Partners! Matter Venture Partners is a Silicon Valley–headquartered hard?tech venture firm with deep expertise in scaling platform technologies, including those at the biotech × AI frontier . They’ve backed synthetic biology efforts through stealth-stage biotech–AI startups, and are active in biotech programs aiming to engineer biology with computational tools.
	InfoEdge Ventures	Investor	2008	Investor
Hi we’re InfoEdge Ventures! InfoEdge Ventures is a deep-tech focused VC fund based in India, investing across AI, healthcare, and next-gen data platforms. Through its participation in Biostate AI’s Series A, InfoEdge is actively backing the convergence of synthetic biology and AI for scalable, precision molecular diagnostics.
	Mana Ventures	Investor	2006	Investor
Hi we’re Mana Ventures! Mana Ventures is a San Francisco–based early?stage venture firm and syndicate that invests across deep tech—including biotech and synthetic biology—alongside AI, robotics, space, and healthtech . They back AI?infused bio and synthetic biology startups as part of their deep tech thesis, offering hands?on support via their collective of operators and deep?tech founders to help scale transformative bio platforms.
	Gaingels	Investor	2015	Synthetic Biology
Hi we’re Gaingels! Gaingels is a U.S.-based venture syndicate focused on advancing diversity and inclusion by investing in companies with LGBTQIA+ and underrepresented leadership. In the synthetic biology space, Gaingels co-invests alongside top-tier VCs to back innovative biotech startups developing next-gen therapeutics, engineered cells, and genomic platforms.
	BrightEdge - American Cancer Society	Investor	2018	Investor
Hi we’re BrightEdge - American Cancer Society! BrightEdge?Ventures is the investment and innovation arm of the American Cancer Society, providing mission-aligned, donor-funded capital to early-stage companies developing cutting-edge, cancer-focused therapeutics, diagnostics, and technologies . They’ve deployed over $43?million across more than 21 oncology-centric startups—such as Freenome and Modifi Biopharma—using a Cancer Impact Investment Framework to drive both scientific progress and social equity